We offer many prenatal evaluations, fetal monitoring and screening tools that are designed to answer your questions, and detect or rule out potential issues with your baby’s development. Any information learned during pregnancy about fetal abnormalities is used to develop an individualized treatment and delivery plan before birth.
Common screenings and diagnostic procedures include:
This screening at 15 weeks involves extracting a small sample of amniotic fluid to identify or rule out chromosome abnormalities such as Down syndrome, birth defects such as spina bifida, or genetic conditions, such as cystic fibrosis.
Carrier screening can help determine if you or your partner could pass a genetic condition on to your child. Testing examines DNA for changes in a number of genes to determine if a parent is a carrier. Healthy people with no family history can be carriers for genetic disorders. While most people get reassuring results, we will discuss further testing options if an increased risk is identified.
Cervical Length Assessment:
This examination uses transvaginal ultrasound to verify an incidental finding of a potentially short cervix that could lead to preterm delivery.
Cell-Free DNA Screening:
This is a blood test done after 9 weeks of pregnancy. Small pieces of genetic material (DNA) from the pregnancy are in a mother’s blood and are tested to check if a baby is at higher risk for Down syndrome and other genetic chromosomal conditions. This is a screening test and does not give a definite answer. Further testing maybe done if cell‐free DNA screening indicates a pregnancy is at high risk.
Chorionic Villus Sampling (CVS):
This diagnostic test at 10-12 weeks takes a sample of the developing placenta for laboratory analysis to identify or rule out chromosome abnormalities, such as Down syndrome and certain genetic disorders, such as cystic fibrosis.
This specialized ultrasound screening measures blood flow through a variety of blood vessels including the umbilical cord and brain.
Fetal Blood Sampling (Cordocentensis):
This blood test takes a small amount of baby’s blood from the umbilical cord for laboratory analysis to help in diagnosing and monitoring a variety of conditions.
This special ultrasound evaluates the structure and function of baby’s heart before birth to detect congenital heart defect.
Microarray Analysis Screening:
This is a detailed test that looks for extra or missing pieces of genetic material (DNA) which may cause problems with growth and development. It can detect a variety of genetic conditions and is performed on blood, amniotic fluid or placental tissue.
This state-of-the-art imaging technique evaluates baby’s size, position and development in diagnosing developmental abnormalities.
Ultrascreen Instant Risk Assessment/First Trimester Screening:
This early pregnancy screening is done at 11-13 weeks and combines a blood test with ultrasound to deliver a personalized risk assessment for Down syndrome, trisomy 18 and trisomy 13.
This blood test administered at 15-22 weeks screens for open neural tube defects (NTDs), such as spina bifida and anencephaly, abdominal wall defects, and chromosome changes, such as Down syndrome and trisomy 18.